How accelerated atherosclerosis in SLE has changed our management of the disorder.
Basic science insights along with the assessment of risk factors so clearly documented by the Canadian and Hopkins cohorts in earlier papers of this special issue have clearly led to a change in the way rheumatologists manage SLE. This review will highlight specific ways it should alter our day to day treatment of lupus patients.
Hallegua
D S
DS
Division of Rheumatology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA, USA.
Wallace
D J
DJ
D017152:Antibodies, Antiphospholipid / Q000378:metabolism; D001161:Arteriosclerosis / Q000209:etiology* / Q000276:immunology; D003327:Coronary Disease / Q000175:diagnosis / Q000209:etiology; D006710:Homocysteine / Q000097:blood; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000276:immunology / Q000628:therapy*; D012307:Risk Factors
D017152:Antibodies, Antiphospholipid; D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; D006710:Homocysteine